详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Immune Profiles of Tumor Microenvironment and Clinical Prognosis among Women with Triple-Negative Breast Cancer.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center forBreast, West China Hospital, Sichuan University, Chengdu, Sichuan, China [2]Laboratory of Pathology, West China Hospital, Sichuan University, Chengdu,Sichuan, China [3]Department of Medical Epidemiology and Biostatistics,Karolinska Institutet, Stockholm, Sweden [4]Novogene Bioinformatics Institute,Beijing, China [5]Breast Medical Oncology, Clinical Research Center for Breast,West China Hospital, Sichuan University, Chengdu, Sichuan, China

出处：

DOI：

ISSN：

摘要：

The impact of the immune landscape of the microenvironment on cancer progression is not well understood for triple-negative breast cancer (TNBC). We, therefore, aimed to examine the association of immune cell enrichment scores as a proxy for immune profiles of tumor microenvironment with TNBC prognosis. We included 76 patients with TNBC diagnosed between 2008 to 2016 in West China Hospital and 158 patients with TNBC from The Cancer Genome Atlas. On the basis of transcriptome data, we calculated the overall ImmuneScore and type-specific enrichment scores for 34 types of immune cells, using xCell, a gene signature-based method. HRs of recurrence-free survival (RFS) and overall survival (OS) were calculated by Cox proportional hazards models. During the median follow-up time of 2.8 (0.1-9.8) years, 42 patients had a recurrence, and 34 patients died. The overall ImmuneScore and most immune cell enrichment scores were relatively higher in tumors than normal tissues. A higher enrichment score of plasma cells was associated with favorable RFS [HR 0.45; 95% confidence interval (CI), 0.27-0.73] and OS (HR 0.32; 95% CI, 0.17-0.61). The score of CD4+ central memory T cell (Tcm) was negatively associated with RFS (HR 1.52; 95% CI, 1.17-1.97). Besides, CD4+ Tcm enrichment score was higher in invasive tumors that were not ductal/lobular carcinoma (OR 1.59; 95% CI, 1.06-2.37). Our findings suggest that plasma cells and CD4+ Tcm in the tumor microenvironment may play a role in the subsequent progression of TNBC. This study provides evidence of the role of immune cells in TNBC progression that may have clinical utility. ©2019 American Association for Cancer Research.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2019]版：

大类 | 2 区医学

小类 | 2 区肿瘤学 2 区公共卫生、环境卫生与职业卫生

最新[2023]版：

大类 | 3 区医学

小类 | 3 区肿瘤学 3 区公共卫生、环境卫生与职业卫生

第一作者：

第一作者机构： [1]Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center forBreast, West China Hospital, Sichuan University, Chengdu, Sichuan, China [2]Laboratory of Pathology, West China Hospital, Sichuan University, Chengdu,Sichuan, China

通讯作者：

通讯机构： [1]Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center forBreast, West China Hospital, Sichuan University, Chengdu, Sichuan, China [2]Laboratory of Pathology, West China Hospital, Sichuan University, Chengdu,Sichuan, China [5]Breast Medical Oncology, Clinical Research Center for Breast,West China Hospital, Sichuan University, Chengdu, Sichuan, China [*1]West China Hospital, Sichuan University, 37 Guoxuexiang, Wuhou District, Chengdu 610041, Sichuan, China [*2]West China Hospital, Sichuan University, 37 Guoxuexiang, Wuhou District, 610041 Chengdu, Sichuan, China

推荐引用方式(GB/T 7714)：

APA：

MLA：